BioSpace News Archive

ISS’s recommendation relies on “the hope that the board finds another transaction that adequately compensates shareholders for Aviragen’s assets.

Peli BioThermal, the global name in temperature controlled packaging, is exhibiting its latest shipper systems and services at the 17th Annual Cool Chain Temperature Controlled Logistics conference.

SafeHeal, a leading innovator in the field of digestive surgery and developer of the Colovac device, announces today that it has enrolled the first five patients in its CE mark study.

In a study of 34 older patients, researchers at Indiana University School of Medicine found that those who scored less well on a standard test of smell were more likely to have more tau protein concentrations in their brains, particularly in regions associated with the sense of smell.

Amgen today announced that it will report its fourth quarter and full year 2017 financial results on Thursday, Feb. 1, 2018, after the close of the U.S. financial markets.

Puma Biotech today announced that on January 16, 2018 the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement stock option to purchase 90,000 shares of Puma common stock to Douglas Hunt in connection with Mr. Hunt’s commencement of employment with the Company as its Senior Vice President of Regulatory Affairs.

Ocular Therapeutix today announced the closing of its underwritten public offering of 7,475,000 shares of its common stock at a public offering price of $5.00 per share.

The drug met its primary and key secondary endpoints, and the medicine was also generally well-tolerated by study participants.

Aravive Biologics and Wuxi Biologics (WuXi Bio, 02269.HK) today announced plans to expand their biologics manufacturing collaboration, based on the rapid success achieved in the process development, scale-up and cGMP manufacture of Aravive’s lead drug candidate, AVB-S6-500 (previously referred to as Aravive-S6).

Avita Medical announced that five abstracts highlighting the compelling clinical data and health economic benefits of RECELL in the treatment of burns have been accepted for presentation at the American Burn Association 50th Annual Meeting to be held from April 10 through 13, 2018 in Chicago, Illinois.